Skip to content

Sympthomatic and prophylactic treatment of drug induced oral dryness in elderly patients with high drug consumption. - Drug induced oral dryness

Sympthomatic and prophylactic treatment of drug induced oral dryness in elderly patients with high drug consumption. - Drug induced oral dryness

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-001468-21-SE
Enrollment
Unknown
Registered
2006-06-01
Start date
2006-08-24
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral dryness is a common problem with serious consquences, especially among elderly individuals. The most common reason for oral dryness is drug consumption. Research has shown that an individual with more than 5 prescribed drug is at risk for oral problems. Drug consumtion is increasing among elderly, mostly due to lack in cooperation in the health care system. Oral dryness have impact on quality of life with eating difficulties and an increased rsik for dental caries.

Interventions

Product Name: Xerodent Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Malic acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 28,6-per tablet IN

Sponsors

Karolinska Institutet
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Swedish talking patients at least 65 years old with at least 6 medically prescribed drugs (not products free for sale) and with at least 10 natural teeth. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Sjögrens syndrom, radiation teraphy against head/neck cancer, ongoing treatment with cytostatics, serious diseases that may undo fulfillment of participation in the study, communication difficulties in swedish.

Design outcomes

Primary

MeasureTime frame
Main Objective: To objectively and subjectively evaluate the effect of 6 months treatment with Xerodent in elderly patients with at least 6 medically prescribed drugs. This is mainly measured by a subjectively valued guestion in a formula with VAS-scales, "How dry is your mouth?";Secondary Objective: The study uses several instruments to evaluate the effect. The objectives are : Objectively valued items in an oral health assessment by nursing staff, questions in two subjectively valued formulas by the study participants, amounts of mutans streptococci and lactobacillus in saliva, amount of unstimulated and stimulated saliva and consumtion of the prescribed study drugs. The study also develop the cooperation between general and dental health around the elderly patients oral health to decrease personal suffering and give society financial advantages. ;Primary end point(s): Oral health is judged by an oral assessment intrument, modified for swedish circumstances. The instrument has a scale from 1-3 in each item where degree 2-3 leads to a recommended activity. The nursing staff will have education in oral health and instruction in the use of the assessment instrument by a registered nurse with a master degree in the area of oral health and long experience of oral health education for nursing staff. The patient judge his/her own oral health with OHIP 14 and VAS scales. OHIP 14 gives a picture of what problems the patient is suffering from most and the VAS-scales give information about in which direction the problems have changed during the study time. Salivary flow is performed by collecting a)unstimulated saliva during 15 minutes and b) stimulated saliva during 5 minutes after having chewed on a bit of paraffin. The amount of saliva is measured by weight. Education in saliva measurement is given to the nursing staff by the project leader (Inger Wårdh). The stimulated saliva is also used as material for a microbial analysis and is sent to a laboratory for analysis o

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026